Breaking News Instant updates and real-time market news.

GMXAY

Genmab

$0.00

(0.00%)

, JNJ

Johnson & Johnson

$136.53

0.53 (0.39%)

06:49
04/16/19
04/16
06:49
04/16/19
06:49

Genmab reports Q1 worldwide net sales of DARZALEX $629M

Genmab (GMXAY) announced that worldwide net sales of DARZALEX as reported by Johnson & Johnson (JNJ) were $629M in the first quarter. Net sales were $352M in the U.S. and $277M in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.

GMXAY

Genmab

$0.00

(0.00%)

JNJ

Johnson & Johnson

$136.53

0.53 (0.39%)

  • 16

    Apr

  • 25

    Apr

GMXAY Genmab
$0.00

(0.00%)

06/20/18
JPMS
06/20/18
UPGRADE
JPMS
Overweight
Genmab upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Quigley upgraded Genmab with an increased price target of 1,150 kroner. The market is overly cautious on Darzalex competition and recent pullback in shares offers an attractive entry point, Quigley tells investors in a research note.
10/01/18
HCWC
10/01/18
INITIATION
HCWC
Buy
Genmab initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Genmab with a Buy rating and DKK 1,600 price target.
12/10/18
DBAB
12/10/18
UPGRADE
DBAB
Buy
Genmab upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Richard Parkes upgraded Genmab to Buy and raised his price target for the shares to DKK 1,250 from DKK 1,220. The analyst says the shares are "well underpinned" by Darzalex while the company's pipeline is maturing.
01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Neutral
Genmab downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Richard Vosser downgraded Genmab to Neutral with an unchanged price target of FKK 1,150. The analyst believes Darzalex's potential is largely reflected in the shares at current levels.
JNJ Johnson & Johnson
$136.53

0.53 (0.39%)

04/05/19
PIPR
04/05/19
NO CHANGE
Target $325
PIPR
Overweight
Piper a 'little cautious' on Q2 results for Cooper Companies
After speaking with a contact lens distributor, Piper Jaffray analyst Matt O'Brien is a "little cautious" on Cooper Companies' fiscal Q2 results. The shift to dailies continues, which is positive for the market as a whole, but Johnson & Johnson (JNJ) and Alcon were more aggressive in calendar Q1, so results for the category "may be a bit unusual," O'Brien tells investors in a research note. In addition to the "odd activity" from the two largest players, the analyst also heard about some "aggressive behavior" from Cooper in recent weeks, which makes him think the company should hit its numbers. He's still bullish on Cooper Companies capturing share in lenses in 2019 and 2020 and keeps an Overweight rating on the name.
04/08/19
PIPR
04/08/19
NO CHANGE
Target $20
PIPR
Overweight
Immunomedics deal with J&J indicates sacituzumab re-filing, says Piper Jaffray
Immunomedics (IMMU) this morning announced that it has entered into an agreement with Johnson & Johnson (JNJ) to provide detailing services to J&J for erdafitinib in the U.S. through Q1 of 2020, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. The analyst believes the deal will provide incremental revenue to Immunomedics while allowing the company to keep its sacituzumab-trained sales team on board while offsetting some of the costs. Further, the Q1 of 2020 termination suggests a potential timeline for a sacituzumab re-filing and approval, says Catanzaro, who notes Immunomedics has not yet provided guidance. The analyst remains comfortable with his mid-2020 approval timing for sacituzumab and keeps an Overweight rating on Immunomedics with a $20 price target.
04/09/19
NEED
04/09/19
UPGRADE
Target $3
NEED
Buy
Geron upgraded to Buy from Hold at Needham
Needham analyst Chad Messer upgraded Geron (GERN) to Buy with a price target of $3, saying the return of development rights for imetelstat in September by Janssen (JNJ) has created a "buying opportunity". The analyst cites the program's subsequent readouts from Phase II IMbark and IMerge studies in myelofibrosis and myelodysplastic syndrome, which he states has "established efficacy in both patient populations." Messer further contends that big pharma passing on imetelstat does not reflect a fundamental issue with the drug itself.
04/09/19
PIPR
04/09/19
NO CHANGE
Target $32
PIPR
Neutral
Alkermes' ALPINE data an incremental positive, says Piper Jaffray
After Alkermes (ALKS) reported this morning that its ALPINE trial met its primary endpoint and that Aristada showed similar efficacy to the current market leader, Invega Sustenna, at all time points assessed, Piper Jaffray analyst Danielle Brill said she views the data as an incremental positive. However, she thinks it will be challenging to capture share from Johnson & Johnson (JNJ), telling investors that she is "not sure these data will be enough to move the needle." Brill maintains a Neutral rating on Alkermes.

TODAY'S FREE FLY STORIES

LKQ

LKQ Corp.

$31.46

0.12 (0.38%)

06:16
04/25/19
04/25
06:16
04/25/19
06:16
Earnings
LKQ Corp. reports Q1 adjusted EPS 56c, consensus 56c »

Reports Q1 revenue $3.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    May

  • 13

    May

  • 14

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 13

    Nov

FBC

Flagstar Bancorp

$35.44

0.355 (1.01%)

06:16
04/25/19
04/25
06:16
04/25/19
06:16
Downgrade
Flagstar Bancorp rating change  »

Flagstar Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 13

    May

  • 21

    May

  • 11

    Jun

  • 20

    Jun

WYNN

Wynn Resorts

$144.35

1.35 (0.94%)

06:15
04/25/19
04/25
06:15
04/25/19
06:15
Upgrade
Wynn Resorts rating change  »

Wynn Resorts upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

SAVE

Spirit Airlines

$58.30

0.82 (1.43%)

06:15
04/25/19
04/25
06:15
04/25/19
06:15
Downgrade
Spirit Airlines rating change  »

Spirit Airlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 21

    May

  • 12

    Jun

  • 13

    Nov

PNM

PNM Resources

$45.22

0.33 (0.74%)

06:15
04/25/19
04/25
06:15
04/25/19
06:15
Upgrade
PNM Resources rating change  »

PNM Resources upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 21

    May

BA

Boeing

$375.32

1.28 (0.34%)

, EADSY

Airbus

$0.00

(0.00%)

06:14
04/25/19
04/25
06:14
04/25/19
06:14
Periodicals
Boeing removes 210 orders from backlog after Jet stops operations, Reuters says »

Boeing (BA) has dropped…

BA

Boeing

$375.32

1.28 (0.34%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 30

    Apr

  • 29

    May

  • 05

    Jun

DAN

Dana

$20.13

-0.16 (-0.79%)

, F

Ford

$9.58

0.08 (0.84%)

06:14
04/25/19
04/25
06:14
04/25/19
06:14
Hot Stocks
Dana, Motiv announce collaboration on Ford F-550 for commercial fleet use »

Dana (DAN) and Motiv…

DAN

Dana

$20.13

-0.16 (-0.79%)

F

Ford

$9.58

0.08 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 02

    May

  • 03

    May

  • 09

    May

  • 05

    Jun

  • 24

    Jul

  • 23

    Oct

FBNC

First Bancorp

06:14
04/25/19
04/25
06:14
04/25/19
06:14
Upgrade
First Bancorp rating change  »

First Bancorp upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

PYPL

PayPal

$107.18

0.27 (0.25%)

06:14
04/25/19
04/25
06:14
04/25/19
06:14
Hot Stocks
Happy Returns announces strategic investment from PayPal »

Happy Returns announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 14

    May

  • 22

    May

  • 03

    Jun

  • 11

    Jun

SAP

SAP

$129.01

14.17 (12.34%)

06:14
04/25/19
04/25
06:14
04/25/19
06:14
Upgrade
SAP rating change  »

SAP upgraded to Hold from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

WNS

WNS Holdings

$56.45

0.73 (1.31%)

06:14
04/25/19
04/25
06:14
04/25/19
06:14
Earnings
WNS Holdings sees FY20 adjusted EPS $2-67-$2.90, consensus $2.81 »

Sees FY20 revenue less…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 23

    May

NOK

Nokia

$5.78

-0.015 (-0.26%)

06:14
04/25/19
04/25
06:14
04/25/19
06:14
Earnings
Nokia sees FY20 EPS EUR 0.37-EUR 0.42 »

Sees FY20 non-IFRS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 20

    May

NTB

Butterfield

$37.30

-0.18 (-0.48%)

06:13
04/25/19
04/25
06:13
04/25/19
06:13
Earnings
Butterfield reports Q1 EPS 96c, consensus 88c »

Net interest margin for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

  • 30

    Apr

WNS

WNS Holdings

$56.45

0.73 (1.31%)

06:12
04/25/19
04/25
06:12
04/25/19
06:12
Earnings
WNS Holdings reports Q4 adjusted EPS 73c, consensus 68c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 23

    May

NOK

Nokia

$5.78

-0.015 (-0.26%)

06:12
04/25/19
04/25
06:12
04/25/19
06:12
Earnings
Nokia sees FY19 EPS EUR 0.25-EUR 0.29 »

Sees FY19 non-IFRS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 20

    May

FB

Facebook

$182.64

-1.13 (-0.61%)

06:12
04/25/19
04/25
06:12
04/25/19
06:12
Upgrade
Facebook upgraded to Buy from Neutral at UBS »

UBS analyst Eric Sheridan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

WCN

Waste Connections

$89.28

0.01 (0.01%)

06:11
04/25/19
04/25
06:11
04/25/19
06:11
Upgrade
Waste Connections rating change at Stifel »

Waste Connections…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 05

    May

  • 17

    May

  • 05

    Jun

SMMF

Summit Financial Group

$26.05

-0.2 (-0.76%)

06:11
04/25/19
04/25
06:11
04/25/19
06:11
Earnings
Summit Financial Group reports Q1 EPS 56c, consensus 54c »

Net interest margin for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

CRR

CARBO Ceramics

$3.35

-0.01 (-0.30%)

06:11
04/25/19
04/25
06:11
04/25/19
06:11
Earnings
Breaking Earnings news story on CARBO Ceramics »

CARBO Ceramics backs FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 21

    May

NOK

Nokia

$5.78

-0.015 (-0.26%)

06:10
04/25/19
04/25
06:10
04/25/19
06:10
Earnings
Nokia reports Q1 EPS (EUR 0.02) vs. EUR 0.02 last year »

Reports Q1 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 20

    May

PRLB

Proto Labs

$117.21

3.29 (2.89%)

06:10
04/25/19
04/25
06:10
04/25/19
06:10
Earnings
Proto Labs reports Q1 non-GAAP EPS 69, consensus 70c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 15

    May

  • 16

    May

  • 28

    May

  • 28

    May

  • 05

    Jun

CRR

CARBO Ceramics

$3.35

-0.01 (-0.30%)

06:09
04/25/19
04/25
06:09
04/25/19
06:09
Earnings
CARBO Ceramics reports Q1 EPS (73c), consensus (55c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 21

    May

XEL

Xcel Energy

$55.44

0.27 (0.49%)

06:09
04/25/19
04/25
06:09
04/25/19
06:09
Earnings
Breaking Earnings news story on Xcel Energy »

Xcel Energy backs 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 21

    May

  • 17

    Jun

XCEL

EXCEL ENERGY INC.

$0.00

(0.00%)

06:08
04/25/19
04/25
06:08
04/25/19
06:08
Earnings
Excel Energy reports Q1 EPS 61c, consensus 61c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WST

West Pharmaceutical

$115.19

(0.00%)

06:07
04/25/19
04/25
06:07
04/25/19
06:07
Earnings
West Pharmaceutical raises FY19 adj. EPS view to $2.80-$2.90 from $2.77-$2.89 »

Consensus $2.86. Backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 07

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.